The addition of Jill Castilla to CorriXR’s Board of Directors signals a strategic move to enhance the company’s financial and operational leadership. Castilla’s deep experience in both the public and private sectors, including her work with the Federal Reserve and as a driving force behind economic recovery during the pandemic, positions CorriXR to navigate complex financial landscapes while pushing forward with innovative gene therapies in oncology. Her track record of success in banking and civic leadership offers immense value as CorriXR aims to overcome drug resistance in cancer treatment.